297 related articles for article (PubMed ID: 19818482)
1. Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators.
Hatano Y; Man MQ; Uchida Y; Crumrine D; Mauro TM; Feingold KR; Elias PM; Holleran WM
J Allergy Clin Immunol; 2010 Jan; 125(1):160-9.e1-5. PubMed ID: 19818482
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of combined peroxisome proliferator-activated receptor-α ligand and glucocorticoid therapy in a murine model of atopic dermatitis.
Hatano Y; Elias PM; Crumrine D; Feingold KR; Katagiri K; Fujiwara S
J Invest Dermatol; 2011 Sep; 131(9):1845-52. PubMed ID: 21633371
[TBL] [Abstract][Full Text] [Related]
3. Topical application of PPARα (but not β/δ or γ) suppresses atopic dermatitis in NC/Nga mice.
Chiba T; Takeuchi S; Esaki H; Yamamura K; Kurihara Y; Moroi Y; Furue M
Allergy; 2012 Jul; 67(7):936-42. PubMed ID: 22583373
[TBL] [Abstract][Full Text] [Related]
4. Panduratin A, an activator of PPAR-α/δ, suppresses the development of oxazolone-induced atopic dermatitis-like symptoms in hairless mice.
Kim MS; Pyun HB; Hwang JK
Life Sci; 2014 Mar; 100(1):45-54. PubMed ID: 24530874
[TBL] [Abstract][Full Text] [Related]
5. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis.
Demerjian M; Choi EH; Man MQ; Chang S; Elias PM; Feingold KR
Exp Dermatol; 2009 Jul; 18(7):643-9. PubMed ID: 19236478
[TBL] [Abstract][Full Text] [Related]
6. Pseudoceramide stimulates peroxisome proliferator-activated receptor-α expression in a murine model of atopic dermatitis: molecular basis underlying the anti-inflammatory effect and the preventive effect against steroid-induced barrier impairment.
Lee SE; Jung MK; Oh SJ; Jeong SK; Lee SH
Arch Dermatol Res; 2015 Nov; 307(9):781-92. PubMed ID: 26121942
[TBL] [Abstract][Full Text] [Related]
7. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing.
Man MQ; Choi EH; Schmuth M; Crumrine D; Uchida Y; Elias PM; Holleran WM; Feingold KR
J Invest Dermatol; 2006 Feb; 126(2):386-92. PubMed ID: 16374473
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges.
Man MQ; Hatano Y; Lee SH; Man M; Chang S; Feingold KR; Leung DY; Holleran W; Uchida Y; Elias PM
J Invest Dermatol; 2008 Jan; 128(1):79-86. PubMed ID: 17671515
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of an acidic stratum corneum prevents emergence of murine atopic dermatitis.
Hatano Y; Man MQ; Uchida Y; Crumrine D; Scharschmidt TC; Kim EG; Mauro TM; Feingold KR; Elias PM; Holleran WM
J Invest Dermatol; 2009 Jul; 129(7):1824-35. PubMed ID: 19177139
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
[TBL] [Abstract][Full Text] [Related]
11. PPARgamma activators stimulate aquaporin 3 expression in keratinocytes/epidermis.
Jiang YJ; Kim P; Lu YF; Feingold KR
Exp Dermatol; 2011 Jul; 20(7):595-9. PubMed ID: 21457357
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis.
Staumont-Sallé D; Abboud G; Brénuchon C; Kanda A; Roumier T; Lavogiez C; Fleury S; Rémy P; Papin JP; Bertrand-Michel J; Tercé F; Staels B; Delaporte E; Capron M; Dombrowicz D
J Allergy Clin Immunol; 2008 Apr; 121(4):962-8.e6. PubMed ID: 18249437
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation.
Mao-Qiang M; Fowler AJ; Schmuth M; Lau P; Chang S; Brown BE; Moser AH; Michalik L; Desvergne B; Wahli W; Li M; Metzger D; Chambon PH; Elias PM; Feingold KR
J Invest Dermatol; 2004 Aug; 123(2):305-12. PubMed ID: 15245430
[TBL] [Abstract][Full Text] [Related]
14. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production.
Fowler AJ; Sheu MY; Schmuth M; Kao J; Fluhr JW; Rhein L; Collins JL; Willson TM; Mangelsdorf DJ; Elias PM; Feingold KR
J Invest Dermatol; 2003 Feb; 120(2):246-55. PubMed ID: 12542530
[TBL] [Abstract][Full Text] [Related]
15. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate.
Takacs ML; Abbott BD
Toxicol Sci; 2007 Jan; 95(1):108-17. PubMed ID: 17047030
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.
Li AC; Binder CJ; Gutierrez A; Brown KK; Plotkin CR; Pattison JW; Valledor AF; Davis RA; Willson TM; Witztum JL; Palinski W; Glass CK
J Clin Invest; 2004 Dec; 114(11):1564-76. PubMed ID: 15578089
[TBL] [Abstract][Full Text] [Related]
17. Establishment of an atopic dermatitis-like skin model in a hairless mouse by repeated elicitation of contact hypersensitivity that enables to conduct functional analyses of the stratum corneum with various non-invasive biophysical instruments.
Matsumoto K; Mizukoshi K; Oyobikawa M; Ohshima H; Tagami H
Skin Res Technol; 2004 May; 10(2):122-9. PubMed ID: 15059180
[TBL] [Abstract][Full Text] [Related]
18. Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model.
Yoon NY; Jung My; Kim DH; Lee HJ; Choi EH
Arch Dermatol Res; 2015 Sep; 307(7):569-81. PubMed ID: 25786383
[TBL] [Abstract][Full Text] [Related]
19. Co-treatment with retinyl retinoate and a PPARα agonist reduces retinoid dermatitis.
Kim B; Kim JE; Kim H; Lee JD; Choi KY; Lee SH
Int J Dermatol; 2012 Jun; 51(6):733-41. PubMed ID: 22607296
[TBL] [Abstract][Full Text] [Related]
20. Expressions of peroxisome proliferator-activated receptors (PPARs) are directly influenced by permeability barrier abrogation and inflammatory cytokines and depressed PPARα modulates expressions of chemokines and epidermal differentiation-related molecules in keratinocytes.
Adachi Y; Hatano Y; Sakai T; Fujiwara S
Exp Dermatol; 2013 Sep; 22(9):606-8. PubMed ID: 23947677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
